- PFS benefit of maintenance niraparib extends to patients with platinum-sensitive, recurrent ovarian cancer who had a partial response to their last platinum-based chemotherapy, regardless of BRCA status.
Why this matters
- Findings support niraparib maintenance therapy regardless of response to the last platinum-based therapy.
- Data from a multicenter, double-blind, phase 3 ENGOT-OV16/NOVA trial of 553 patients with recurrent ovarian cancer who responded to last platinum therapy.
- Patients were randomly assigned 2:1 to receive maintenance niraparib or placebo.
- Funding: TESARO (a GSK company).
- 203 had germline BRCA mutation.
- 49% of patients had a partial response to the last platinum therapy.
- Patients who received niraparib had significantly prolonged PFS vs placebo, regardless of the best response to the last platinum-based therapy.
- gBRCA-mutated patients with partial response (HR, 0.24; P=.0001) and with complete response (HR, 0.30; P<.0001>
- non-gBRCA-mutated patients with partial response (HR, 0.35; P<.0001 and with complete response p=".0082).</li">
- Post hoc analysis.